- Home
- OPAD vs ATOS Comparison
OPAD vs ATOS Comparison
Compare OPAD & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPAD
- ATOS
- Stock Information
- Founded
- OPAD 2015
- ATOS 2009
- Country
- OPAD United States
- ATOS United States
- Employees
- OPAD N/A
- ATOS N/A
- Industry
- OPAD Real Estate
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- OPAD Finance
- ATOS Health Care
- Exchange
- OPAD Nasdaq
- ATOS Nasdaq
- Market Cap
- OPAD 117.4M
- ATOS 140.9M
- IPO Year
- OPAD N/A
- ATOS 2012
- Fundamental
- Price
- OPAD $3.47
- ATOS $1.04
- Analyst Decision
- OPAD Hold
- ATOS Strong Buy
- Analyst Count
- OPAD 6
- ATOS 3
- Target Price
- OPAD $5.19
- ATOS $7.00
- AVG Volume (30 Days)
- OPAD 44.1K
- ATOS 888.9K
- Earning Date
- OPAD 11-04-2024
- ATOS 11-12-2024
- Dividend Yield
- OPAD N/A
- ATOS N/A
- EPS Growth
- OPAD N/A
- ATOS N/A
- EPS
- OPAD N/A
- ATOS N/A
- Revenue
- OPAD $985,005,000.00
- ATOS N/A
- Revenue This Year
- OPAD N/A
- ATOS N/A
- Revenue Next Year
- OPAD $37.39
- ATOS N/A
- P/E Ratio
- OPAD N/A
- ATOS N/A
- Revenue Growth
- OPAD N/A
- ATOS N/A
- 52 Week Low
- OPAD $2.57
- ATOS $0.70
- 52 Week High
- OPAD $10.89
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- OPAD 41.16
- ATOS 28.69
- Support Level
- OPAD $3.73
- ATOS $1.17
- Resistance Level
- OPAD $5.13
- ATOS $1.30
- Average True Range (ATR)
- OPAD 0.45
- ATOS 0.07
- MACD
- OPAD -0.13
- ATOS -0.01
- Stochastic Oscillator
- OPAD 10.22
- ATOS 12.50
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.